Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions

References

• Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–953.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140:e125–e151.
   PubMed Web of Science ®Google Scholar
• Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian stroke registry. Eur Heart J. 2004;25(19):1734–1740.
   PubMed Web of Science ®Google Scholar
• Steffel J, Collins R, Antz M, et al. European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676.
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272.
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Collet JP, Caterina R, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2017;19(11):1757–1758.
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.
   PubMed Web of Science ®Google Scholar
• Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol. 2011;8(10):602–606.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Suárez-Gea ML, Calvo-Rojas G, et al. Discovery of anticoagulant drugs: a historical perspective. Curr Drug Discov Technol. 2012;9(2):83–104.
   PubMedGoogle Scholar
• Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84–91.
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;2013:640723.
   PubMedGoogle Scholar
• Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest. 2013;144(5):1555–1563.
   PubMed Web of Science ®Google Scholar
• Proietti M, Lip GYH. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT 2 R 2 score. Eur Heart J Cardiovasc Pharmacother. 2015;1(3):150–152.
   PubMedGoogle Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962.
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández AI, et al. Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2016;68(23):2508–2521.
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, et al. Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients. Br J Clin Pharmacol. 2016;82(3):633–644.
   PubMed Web of Science ®Google Scholar
• Hirschl M, Kundi M. Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data. Vasa. 2019;48(2):134–147.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Briere JB, Fauchier L, et al. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Mark Access Health Policy. 2019;7(1):1574541.
   PubMedGoogle Scholar
• Wang YP, Kehar R, Iansavitchene A, et al. Bleeding risk in nonvalvular atrial fibrillation patients receiving direct oral anticoagulants and warfarin: a systematic review and meta-analysis of observational studies. TH Open. 2020;4(3):e145–e152.
   PubMedGoogle Scholar
• Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart. 2006;92(2):155–161.
   PubMed Web of Science ®Google Scholar
• Gupta S, Um KJ, Pandey A, et al. Direct oral anticoagulants versus vitamin k antagonists in patients undergoing cardioversion for atrial fibrillation: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2019;33(3):339–352.
   PubMed Web of Science ®Google Scholar
• Asad ZUA, Akhtar KH, Jafry AH, et al. Uninterrupted versus interrupted direct oral anticoagulation for catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2021;32(7):1995–2004.
   PubMed Web of Science ®Google Scholar
• American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics - 2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492.
   PubMed Web of Science ®Google Scholar
• Brunetti ND, Tricarico L, De Gennaro L, et al. Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: dual or triple approach? Int J Cardiol Heart Vasc. 2020;29:100569.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–1214.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):120–129.
   PubMed Web of Science ®Google Scholar
• Collet JP, Van Belle E, Thiele H, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022;43(29):2783–2797.
   PubMed Web of Science ®Google Scholar
• Van Mieghem NM, Unverdorben M, Hengstenberg C. Edoxaban versus Vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385(23):2150–2160.
   PubMed Web of Science ®Google Scholar
• Greco A, Capodanno D. Anticoagulation after transcatheter aortic valve implantation: current status. Interv Cardiol. 2020;15:e02.
   PubMedGoogle Scholar
• Dawwas GK, Dietrich E, Cuker A, et al. Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population-based cohort study. Ann Intern Med. 2021;174(7):910–919.
   PubMed Web of Science ®Google Scholar
• He Q, Sze CY, Shum TY, et al. Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with valvular heart diseases: a meta-analysis. BMC Cardiovasc Disord. 2019;19(1):113.
   PubMedGoogle Scholar
• Guimarães HP, Lopes RD, de Barros E Silva PGM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383(22):2117–2126.
   PubMed Web of Science ®Google Scholar
• Karthikeyan G, Connolly SJ, Ntsekhe M, et al. The INVICTUS rheumatic heart disease research program: rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. Am Heart J. 2020;225:69–77.
   PubMed Web of Science ®Google Scholar
• Halvorsen S, Storey RF, Rocca B, et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2017;38(19):1455–1462.
   PubMed Web of Science ®Google Scholar
• Staerk L, Lip GY, Olesen JB, et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ. 2015;351:h5876.
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Alcubilla P, Calvo-Rojas G, et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol. 2021;77(24):2987–3001.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke. 2015;46(8):2175–2182.
   PubMed Web of Science ®Google Scholar
• Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–e418.
   PubMed Web of Science ®Google Scholar
• Altavilla R, Caso V, Bandini F, et al. Anticoagulation after stroke in patients with atrial fibrillation. Stroke. 2019;50(8):2093–2100.
   PubMed Web of Science ®Google Scholar
• Best JG, Arram L, Ahmed N, et al. Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): protocol for a randomized controlled trial. Int J Stroke. 2022;17(5):583–589.
   PubMed Web of Science ®Google Scholar
• Åsberg S, Hijazi Z, Norrving B, et al. Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial. Trials. 2017;18(1):581.
   PubMedGoogle Scholar
• King BT, Lawrence PD, Milling TJ, et al. Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): methodology of a pragmatic, response-adaptive, prospective randomized clinical trial. Int J Stroke. 2019;14(9):977–982.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G, Giustozzi M, et al. Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes. Eur Stroke J. 2020;5(4):374–383.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Bandini F, Agnelli G, et al. Hemorrhagic transformation in patients with acute ischemic stroke and atrial fibrillation: time to initiation of oral anticoagulant therapy and outcomes. J Am Heart Assoc. 2018;7(22):e010133.
   PubMed Web of Science ®Google Scholar
• Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429–438.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Acampa M, Norata D, et al. A critical assessment of the current pharmacotherapy for the treatment of embolic strokes of undetermined source. Expert Opin Pharmacother. 2022;23(8):905–915.
   PubMed Web of Science ®Google Scholar
• Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–2201.
   PubMed Web of Science ®Google Scholar
• Diener HC, Sacco RL, Easton JD, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906–1917.
   PubMed Web of Science ®Google Scholar
• Kamel H, Pearce LA, Ntaios G, et al. Atrial cardiopathy and nonstenosing large artery plaque in patients with embolic stroke of undetermined source. Stroke. 2020;51(3):938–943.
   PubMed Web of Science ®Google Scholar
• Healey JS, Gladstone DJ, Swaminathan B, et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol. 2019;76(7):764–773.
   PubMed Web of Science ®Google Scholar
• Geisler T, Poli S, Meisner C, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design. Int J Stroke. 2017;12(9):985–990.
   PubMed Web of Science ®Google Scholar
• Kamel H, Bartz TM, Elkind MSV, et al. Atrial cardiopathy and the risk of ischemic stroke in the CHS (Cardiovascular Health Study). Stroke. 2018;49(4):980–986.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68(24):2597–2604.
   PubMed Web of Science ®Google Scholar
• Ruiz Ortiz M, Muñiz J, Raña Míguez P, et al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577–1583.
   PubMed Web of Science ®Google Scholar
• Yao X, Shah ND, Sangaralingham LR, et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–2790.
   PubMed Web of Science ®Google Scholar
• Sanghai S, Wong C, Wang Z, et al. Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study. J Am Heart Assoc. 2020;9(6):e014108.
   PubMed Web of Science ®Google Scholar
• Rohla M, Pecen L, Cemin R, et al. Reclassification, thromboembolic, and major bleeding outcomes using different estimates of renal function in anticoagulated patients with atrial fibrillation: insights from the PREFER-in-AF and PREFER-in-AF prolongation registries. Circ Cardiovasc Qual Outcomes. 2021;14(6):e006852.
   PubMed Web of Science ®Google Scholar
• Sabaté M, Vidal X, Ballarin E, et al. Adherence to direct oral anticoagulants in patients with non-valvular atrial fibrillation: a cross-national comparison in Six European Countries (2008-2015). Front Pharmacol. 2021;12:682890.
   PubMed Web of Science ®Google Scholar
• Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on nonvitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117(2):209–218.
   PubMed Web of Science ®Google Scholar
• Clarkesmith DE, Pattison HM, Khaing PH, et al. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev. 2017;4(4):CD008600.
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, García-Fuentes M, Suárez-Gea ML. Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017;12(12):1195–1205.
   PubMed Web of Science ®Google Scholar
• Wheeler AP, Gailani D. The intrinsic pathway of coagulation as a target for antithrombotic therapy. Hematol Oncol Clin North Am. 2016;30(5):1099–1114.
   PubMed Web of Science ®Google Scholar
• Calabria S, Forcesi E, Dondi L, et al. Target population of non-deferrable surgery and uncontrolled severe bleeding related to dabigatran. Cardiovasc Drugs Ther. 2018;32(3):281–286.
   PubMed Web of Science ®Google Scholar
• Fredenburgh JC, Weitz JI. Factor XI as a target for new anticoagulants. Hamostaseologie. 2021;41(2):104–110.
   PubMedGoogle Scholar
• Preis M, Hirsch J, Kotler A, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129(9):1210–1215.
   PubMed Web of Science ®Google Scholar
• Bentley R, Hardy LJ, Scott LJ, et al. Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. Expert Opin Investig Drugs. 2021;30(10):1057–1069.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Heckmann M, Distler J, et al. Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study. Br J Clin Pharmacol. 2022;88(7):3447–3462.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022;399(10333):1383–1390.
   PubMed Web of Science ®Google Scholar
• Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of milvexian in participants with mild or moderate hepatic impairment compared with healthy participants. Clin Pharmacokinet. 2022;61(6):857–867.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161–2172.
   PubMed Web of Science ®Google Scholar
• Yi BA, Freedholm D, Widener N, et al. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa. J Thromb Haemost. 2022;20(2):307–315.
   PubMed Web of Science ®Google Scholar
• Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385(7):609–617.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020;323(2):130–139.
   PubMed Web of Science ®Google Scholar
• Lorentz CU, Verbout NG, Wallisch M, et al. Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial. Arterioscler Thromb Vasc Biol. 2019;39(4):799–809.
   PubMed Web of Science ®Google Scholar
• Lorentz CU, Tucker EI, Verbout NG, et al. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. Blood. 2021;138(22):2173–2184.
   PubMed Web of Science ®Google Scholar
• Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232–240.
   PubMed Web of Science ®Google Scholar
• Walsh M, Bethune C, Smyth A, et al. Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD. Kidney Int Rep. 2021;7(2):200–209.
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and stroke risk: a new target for prevention. Stroke. 2021;52(8):2697–2706.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Li N, Dobrev D. Role of inflammatory signaling in atrial fibrillation. Int J Cardiol. 2019;287:195–200.
   PubMed Web of Science ®Google Scholar
• Hamanaka Y, Sotomi Y, Hirata A, et al. Persistent systemic inflammation is associated with bleeding risk in atrial fibrillation patients. Circ J. 2020;84(3):411–418.
   PubMed Web of Science ®Google Scholar
• Adler Y, Charron P, Imazio M, et al. ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921–2964.
   PubMed Web of Science ®Google Scholar
• Goh CXY, Tan YK, Tan CH, et al. The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis. J Thromb Thrombolysis. 2022;54(1):183–190.
   PubMed Web of Science ®Google Scholar
• Bouabdallaoui N, Tardif JC. Repurposing Colchicine for Heart Disease. Annu Rev Pharmacol Toxicol. 2022;62:121–129.
   PubMed Web of Science ®Google Scholar
• Verma S, Eikelboom JW, Nidorf SM, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015;15:96.
   PubMed Web of Science ®Google Scholar
• Wang A, Green JB, Halperin JL, et al. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol. 2019;74(8):1107–1115.
   PubMed Web of Science ®Google Scholar
• Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050–2060.
   PubMed Web of Science ®Google Scholar
• Pathak R, Middeldorp M, Lau D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation. J Am Coll Cardiol. 2014;64(21):2222–2231.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–1316.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg Bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120(13):1174–1180.
   PubMed Web of Science ®Google Scholar
• Jackevicius CA, Tsadok MA, Essebag V, et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart. 2017;103(17):1331–1338.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2):e003074.
   PubMed Web of Science ®Google Scholar
• Brízido C, Ferreira AM, Lopes P, et al. Medication adherence to direct anticoagulants in patients with non-valvular atrial fibrillation - A real world analysis. Revista portuguesa de cardiologia (Engl Ed). 2021;40(9):669–675.
   PubMed Web of Science ®Google Scholar